No Data
No Data
Yifan Pharmaceutical's Unit Gets Regulatory Nod for Muscle Pain Reliever
Yifan Pharmaceutical (002019.SZ): obtained the pharmaceutical registration certificate for Mesoba Mo injection.
On August 6th, Gelonhui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the Approval of Registration Certificate for Mosapramine Injection from the National Medical Products Administration on August 5, 2024. Mosapramine Injection is mainly used to treat acute skeletal muscle pain or discomfort. According to IQVIA data, the global sales of Mosapramine Injection in 2023 were 40.43 million US dollars. According to Minet data, the domestic sales of Mosapramine Injection in 2023 were 330 million yuan. As of the date of the report disclosure, the company had not yet achieved sales of Mesobom.
Yifan Pharmaceutical (002019.SZ): The price of the company's vitamin B5 product is still running at a low level.
Yifan Pharmaceutical (002019.SZ) stated on the investor communication platform on August 5th that the price of vitamins B5 products is influenced by various factors including but not limited to production capacity, eco-friendly concepts, supply and demand relationship. Currently, the price of the company's vitamin B5 products is still running at a low level.
Yifan Pharmaceutical (002019.SZ): As of July 19, the number of shareholders of the company is 39,467.
Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform on July 25th that as of July 19, 2024, the number of shareholders of the company was 39,467.
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Stock Price Dropped 4.1% Last Week; Retail Investors Would Not Be Happy
Yifan Pharmaceutical: 2024 Interim Performance Forecast
No Data